Analysis of microRNAs in 86 Samples of Cerebrospinal Fluid: A New Possible Diagnostic Tool in Brain Tumor Patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F20%3A00072794" target="_blank" >RIV/65269705:_____/20:00072794 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.nature.com/articles/s41379-020-0481-8" target="_blank" >https://www.nature.com/articles/s41379-020-0481-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41379-020-0481-8" target="_blank" >10.1038/s41379-020-0481-8</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Analysis of microRNAs in 86 Samples of Cerebrospinal Fluid: A New Possible Diagnostic Tool in Brain Tumor Patients

Popis výsledku v původním jazyce

Background: Cerebrospinal fluid (CSF) may represent an ideal source of diagnostic biomarkers of brain tumors. MicroRNAs (miRNAs), short non-coding RNAs involved in the pathogenesis of many cancers including brain tumors, might represent group of new biomarkers. Analysis of CSF miRNAs in brain tumor patients may lead to new promising tools, both diagnostic and prognostic, enabling more precise brain tumor classification and future tailored therapy. Design: Analysis of global miRNA profiles by next-generation sequencing (NGS) has been performed in 89 CSF samples obtained from 32 cases of glioblastomas (GB), 14 low-grade gliomas, 11 meningiomas and 13 brain metastasis patients and 19 non-tumor donors. 4 - 6 mL of CSF samples have been obtained during the lumbar puncture before surgical intervention in brain tumor patients or during standard therapy management of patients with normal-pressure hydrocephalus (non-tumor donors). CleanTag Small RNA Library Prep Kit were used for cDNA library preparation. NextSeq 500 instrument together with Next 500/550 High Output v2 Kit - 75 cycles were used for final sequencing analysis. Results: NGS analysis revealed 22, 12, 35, and 11 CSF miRNAs with different levels in GB, meningiomas, brain metastases, and lowgrade gliomas (adj.p &lt; 0.0005, adj.p &lt; 0.01 and adj.p &lt; 0.005, p &lt; 0.1) respectively, in comparison with non-tumor CSF samples. Levels of 9 miRNAs (let-7a, let-7b, miR-10a, miR-10b, miR-21-3p, miR-30e, miR-140, miR-196a and miR-196b) were validated in independent set of CSF samples (41 GBM, 8 low-grade gliomas, 44 meningiomas, 12 metastasis patients and 21 non-tumor donors) using TaqMan Advanced miRNA Assays. We successfully validated all selected miRNAs identified by NGS to have significantly (adj. p &lt; 0.05) different levels in CSF of GB. In case of meningioma we confirmed 2 out of 5 miRNAs and in brain metastasis 2 out of 6 miRNAs were independently validated. We also successfully validated 5 out 6 miRNAs in low-grade gliomas. we also show miR-10b and miR-196b in CSF to be potential prognostic biomarkers in GB patients. Conclusions: We showed significant differences in CSF miRNA levels in patients with various brain tumors. Our results suggest potential of CSF miRNAs to be useful biomarkers in brain tumors.

Název v anglickém jazyce

Analysis of microRNAs in 86 Samples of Cerebrospinal Fluid: A New Possible Diagnostic Tool in Brain Tumor Patients

Popis výsledku anglicky

Background: Cerebrospinal fluid (CSF) may represent an ideal source of diagnostic biomarkers of brain tumors. MicroRNAs (miRNAs), short non-coding RNAs involved in the pathogenesis of many cancers including brain tumors, might represent group of new biomarkers. Analysis of CSF miRNAs in brain tumor patients may lead to new promising tools, both diagnostic and prognostic, enabling more precise brain tumor classification and future tailored therapy. Design: Analysis of global miRNA profiles by next-generation sequencing (NGS) has been performed in 89 CSF samples obtained from 32 cases of glioblastomas (GB), 14 low-grade gliomas, 11 meningiomas and 13 brain metastasis patients and 19 non-tumor donors. 4 - 6 mL of CSF samples have been obtained during the lumbar puncture before surgical intervention in brain tumor patients or during standard therapy management of patients with normal-pressure hydrocephalus (non-tumor donors). CleanTag Small RNA Library Prep Kit were used for cDNA library preparation. NextSeq 500 instrument together with Next 500/550 High Output v2 Kit - 75 cycles were used for final sequencing analysis. Results: NGS analysis revealed 22, 12, 35, and 11 CSF miRNAs with different levels in GB, meningiomas, brain metastases, and lowgrade gliomas (adj.p &lt; 0.0005, adj.p &lt; 0.01 and adj.p &lt; 0.005, p &lt; 0.1) respectively, in comparison with non-tumor CSF samples. Levels of 9 miRNAs (let-7a, let-7b, miR-10a, miR-10b, miR-21-3p, miR-30e, miR-140, miR-196a and miR-196b) were validated in independent set of CSF samples (41 GBM, 8 low-grade gliomas, 44 meningiomas, 12 metastasis patients and 21 non-tumor donors) using TaqMan Advanced miRNA Assays. We successfully validated all selected miRNAs identified by NGS to have significantly (adj. p &lt; 0.05) different levels in CSF of GB. In case of meningioma we confirmed 2 out of 5 miRNAs and in brain metastasis 2 out of 6 miRNAs were independently validated. We also successfully validated 5 out 6 miRNAs in low-grade gliomas. we also show miR-10b and miR-196b in CSF to be potential prognostic biomarkers in GB patients. Conclusions: We showed significant differences in CSF miRNA levels in patients with various brain tumors. Our results suggest potential of CSF miRNAs to be useful biomarkers in brain tumors.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30109 - Pathology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů